Technical Analysis for GNHAY - Vifor Pharma Ag ADR

Grade Last Price % Change Price Change
grade D 25.1 -0.40% -0.1000
GNHAY closed down 0.4 percent on Thursday, February 7, 2019, on 2 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical GNHAY trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Outside Day Range Expansion -0.40%
Volume Surge Other -0.59%
Gapped Up Strength -0.59%
Narrow Range Bar Range Contraction 0.40%
Gapped Down Weakness 0.40%
Narrow Range Bar Range Contraction -1.38%
Gapped Up Strength -1.38%

Older signals for GNHAY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Vifor Pharma AG develops, manufactures, and distributes pharmaceutical products in Switzerland, Europe, the United States, and internationally. It offers iron products, including Ferinject, Venofer, Maltofer, and Velphoro; Veltassa, a sodium-free potassium binder for the treatment of hyperkalaemia in adult patients; and Mircera, an erythropoiesis-stimulating agent for the treatment of symptomatic anemia associated with chronic kidney diseases. The company also provides infectious diseases/over-the-counter products, such as Broncho-Vaxom, an extract of various bacterial species for the treatment and prevention of recurrent respiratory infections; Uro-Vaxom, an extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections; Dicynone for the prevention and treatment of capillary haemorrhages; Doxium for the oral treatment of diabetic retinopathy; and Aero-OM, an anti-flatulent for the oral treatment. Its development/pre-clinical products include VIT-2763, an oral ferroportin inhibitor, which is Phase I clinical trial for the treatment patients suffering from iron overload; Rayaldee for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) and vitamin D deficiency; Biosimilar epoetin alfa the treatment of anemia associated with CKD, renal failure, and chemotherapy-induced anemia; Avacopan/CCX168, an orally administered inhibitor; CCX140, an orally administered inhibitor of the chemokine receptor; and Vadadustat, an oral investigational hypoxia-inducible factor stabiliser that is in Phase-III development for the treatment of anemia related to CKD. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1927 and is headquartered in St. Gallen, Switzerland.
Medicine RTT Medical Specialties Branches Of Biology Pharmaceutical Pharmaceutical Products Infectious Diseases Chemotherapy Diabetic Retinopathy Chronic Kidney Disease Anemia Chronic Kidney Diseases Organ Failure Erythropoiesis Stimulating Agent Chemotherapy Induced Anemia Iron Products Secondary Hyperparathyroidism Acetic Acids And Velphoro Development/Pre Clinical Products Galenica Including Ferinject Infectious Diseases/Over The Counter Products Iron Overload Maltofer Recurrent Respiratory Infections Recurrent Urinary Tract Infections Renal Failure Sucroferric Oxyhydroxide Symptomatic Anemia Treatment Of Secondary Hyperparathyroidism In Chronic Kidney Disease Vadadustat Velphoro Venofer Vifor Pharma Vit 2763 Vitamin D Deficiency
Is GNHAY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 25.9
52 Week Low 24.4
Average Volume 4,140
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 25.199
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.1000
Resistance 3 (R3) 25.1000 25.1000 25.1000
Resistance 2 (R2) 25.1000 25.1000 25.1000 25.1000
Resistance 1 (R1) 25.1000 25.1000 25.1000 25.1000 25.1000
Pivot Point 25.1000 25.1000 25.1000 25.1000 25.1000
Support 1 (S1) 25.1000 25.1000 25.1000 25.1000 25.1000
Support 2 (S2) 25.1000 25.1000 25.1000 25.1000
Support 3 (S3) 25.1000 25.1000 25.1000
Support 4 (S4) 25.1000